Combination with tyrosine kinase inhibitors & PD-1/PD-L1 inhibitorRationale: Assessing safety of OTX-2002 in combination with standard HCC treatments; c-Myc inhibition restricts tumor growth and may augment other therapies that also control tumor expansion. The gene discussed is PDCD1; the disease is neoplasm.